Clostridium difficile phages: still difficult?

Overview of attention for article published in Frontiers in Microbiology, April 2014
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
1 news outlet
twitter
18 tweeters
wikipedia
1 Wikipedia page
googleplus
1 Google+ user

Readers on

mendeley
72 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
<i>Clostridium difficile</i> phages: still difficult?
Published in
Frontiers in Microbiology, April 2014
DOI 10.3389/fmicb.2014.00184
Pubmed ID
Authors

Hargreaves, Katherine Rose, Clokie, Martha Rebecca Jane, Katherine R. Hargreaves, Martha R. J. Clokie

Abstract

Phages that infect Clostridium difficile were first isolated for typing purposes in the 1980s, but their use was short lived. However, the rise of C. difficile epidemics over the last decade has triggered a resurgence of interest in using phages to combat this pathogen. Phage therapy is an attractive treatment option for C. difficile infection, however, developing suitable phages is challenging. In this review we summarize the difficulties faced by researchers in this field, and we discuss the solutions and strategies used for the development of C. difficile phages for use as novel therapeutics. Epidemiological data has highlighted the diversity and distribution of C. difficile, and shown that novel strains continue to emerge in clinical settings. In parallel with epidemiological studies, advances in molecular biology have bolstered our understanding of C. difficile biology, and our knowledge of phage-host interactions in other bacterial species. These three fields of biology have therefore paved the way for future work on C. difficile phages to progress and develop. Benefits of using C. difficile phages as therapeutic agents include the fact that they have highly specific interactions with their bacterial hosts. Studies also show that they can reduce bacterial numbers in both in vitro and in vivo systems. Genetic analysis has revealed the genomic diversity among these phages and provided an insight into their taxonomy and evolution. No strictly virulent C. difficile phages have been reported and this contributes to the difficulties with their therapeutic exploitation. Although treatment approaches using the phage-encoded endolysin protein have been explored, the benefits of using "whole-phages" are such that they remain a major research focus. Whilst we don't envisage working with C. difficile phages will be problem-free, sufficient study should inform future strategies to facilitate their development to combat this problematic pathogen.

Twitter Demographics

The data shown below were collected from the profiles of 18 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 6%
Spain 1 1%
United Kingdom 1 1%
Colombia 1 1%
Unknown 65 90%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 25 35%
Researcher 12 17%
Student > Bachelor 10 14%
Student > Master 9 13%
Professor 4 6%
Other 12 17%
Readers by discipline Count As %
Agricultural and Biological Sciences 39 54%
Medicine and Dentistry 11 15%
Biochemistry, Genetics and Molecular Biology 8 11%
Immunology and Microbiology 8 11%
Chemistry 3 4%
Other 3 4%

Attention Score in Context

This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 January 2017.
All research outputs
#285,575
of 7,269,211 outputs
Outputs from Frontiers in Microbiology
#112
of 4,961 outputs
Outputs of similar age
#9,151
of 174,910 outputs
Outputs of similar age from Frontiers in Microbiology
#7
of 147 outputs
Altmetric has tracked 7,269,211 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,961 research outputs from this source. They receive a mean Attention Score of 4.0. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 174,910 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 147 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.